Advancing cell therapy in oncology

Wed, 14 Apr 2021 16:52:04 +0000

Filippo Petti, CEO/CFO, Celyad Oncology, Mont-Saint-Guibert, Belgium, summarizes the topics discussed during a panel session on novel cell therapy approaches for oncology at the Cell & Gene Meeting on the Mediterranean 2021 virtual conference. He discusses the importance of building a good manufacturing process in order to deliver novel therapeutics for solid tumor indications, as well as the future commercialization of these therapies, which he believes could reach a similar market presence to other off-the-shelf biological therapies in the future. This interview took place during the Cell & Gene Meeting on the Mediterranean 2021 virtual conference.

]]>

A non-gene edited approach to allogeneic CAR-T development

Sat, 10 Apr 2021 10:58:00 +0000

Filippo Petti, CEO/CFO, Celyad Oncology, Mont-Saint-Guibert, Belgium, describes the benefits of using a non-gene edited approach for the development of single-vector, allogeneic CAR-T cancer therapies. Preliminary data from the ongoing Phase I alloSHRINK study (NCT03692429) in patients with colorectal cancer treated with CYAD-101, a natural killer group 2D (NKG2D) CAR-T candidate encoding the T cell receptor inhibitory molecule (TIM), has highlighted the potential of this approach. He also introduces the recently launched Phase I IMMUNICY-1 study (NCT04613557) investigating CYAD-211, a short hairpin RNA (shRNA)-based CAR T therapy, in patients with multiple myeloma. This interview took place during the Cell & Gene Meeting on the Mediterranean 2021 virtual conference.

]]>

Filippo Petti – VJRegenMed

Advancing cell therapy in oncology

A non-gene edited approach to allogeneic CAR-T development